Page last updated: 2024-12-11

gw 501516

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GW 501516: a selective PPARdelta agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9803963
CHEMBL ID38943
CHEBI ID73726
SCHEMBL ID68714
MeSH IDM0387270

Synonyms (70)

Synonym
HY-10838
2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
gtpl2687
PDSP1_000255
PDSP2_000254
gw-516
gw-501516
gsk-516
gw 501516
2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
gw1516
chembl38943 ,
bdbm28661
gw501516
{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]acetic acid
gw 1516
endurobol
cardarine
gw-1516
chebi:73726 ,
NCGC00241455-01
2-(4-((2-(4-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid
EX-3881
317318-70-0
gsk 516
unii-7i2ha1nu22
7i2ha1nu22 ,
acetic acid, (2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl)methyl)thio)phenoxy)-
AKOS015965103
acetic acid, 2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-
AM20040157
NCGC00241455-02
gw501,516
gw 501,516
gw-501,516
CS-0438
(2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)-1,3-thiazol-5-yl)methyl)thio)phenoxy)acetic acid
S5615
BRD-K14880289-001-01-4
DB05416
SCHEMBL68714
smr004701706
MLS006010753
gw501516 (endurobol)
6T-0058
2-(2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid
2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl)sulfanyl]phenoxy}acetic acid
AC-23001
DTXSID3041037
mfcd09033000
endurobol;gw501516
EX-A723
{2-methyl-4-{{4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl}methylthio}phenoxy}acetic acid, analytical standard
gw501516, >=98% (hplc)
7t1 ,
J-018519
NCGC00241455-08
gw501516(gsk-516)
BCP21491
Q5515069
benzenesulfonylchloride,4-(2-methylpropyl)-(9ci)
SB19569
HMS3674C03
HMS3744O09
CCG-269268
A26949
2-(2-methyl-4-((5-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)methylthio)phenoxy)acetic acid;gw 501516
{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid
gw501516(g)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid 13c exhibited potent hypoglycemic and lipid lowering activity with high oral bioavailability in animal models."( Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P, 2008
)
0.35
" The PPARδ ligands 10a, 11e and 11f showed good bioavailability and in vivo efficacy."( Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
Banerjee, J; Chin, J; Cho, SJ; Choi, H; Choi, J; Hahn, D; Ham, J; Holla, H; Hwang, H; Kang, H; Kim, E; Kim, JA; Kim, S; Ko, J; Lee, HJ; Lee, J; Lee, TG; Lee, W; Nam, SJ; Oh, T; Park, MS; Seok, C; Shin, K; Tak, J; Won, DH; Yang, I, 2012
)
0.38
" Treatment with PPARδ ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576 mice aortas."( Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.
d'Uscio, LV; Das, P; He, T; Katusic, ZS; Santhanam, AV; Younkin, SG, 2012
)
0.38
" Obtained results suggest that in vivo activation of PPARδ prevents eNOS uncoupling, restores bioavailability of NO and may help preserve endothelial function in the BH₄-deficient cerebral circulation."( PPARδ agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.
d'Uscio, LV; He, T; Katusic, ZS; Santhanam, AV, 2012
)
0.38
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" In this study, we hybrid FFA1 agonist AM-4668 with PPARδ agonist GW501516, leading to the identification of orally bioavailable dual agonist 32, which revealed high selectivity over other PPARs."( Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Chen, Y; Deng, L; Hu, L; Li, Z; Liu, B; Xu, Y; Zhang, L; Zhou, Z, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin."( A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
Bodkin, NL; Hansen, BC; Kliewer, SA; Lambert, MH; Lewis, MC; Oliver, WR; Plunket, KD; Russell, CS; Shenk, JL; Snaith, MR; Sternbach, DD; Sznaidman, ML; Willson, TM; Winegar, DA; Xu, HE, 2001
)
0.31
" LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice."( 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
Azimioara, M; Bursulaya, B; Cow, C; Epple, R; Gerken, A; Iskandar, M; Karanewsky, D; Kreusch, A; Martin Seidel, H; Russo, R; Saez, E; Tian, SS; Tuntland, T; Wang, X; Wityak, J; Xie, Y, 2006
)
0.33
" In an in vivo acute dosing model, selected members of this array were shown to induce the expression of pyruvate dehydrogenase kinase-4 (PDK4) and uncoupling protein-3 (UCP3), genes that are known to be involved in energy homeostasis and regulated by PPARdelta in skeletal muscle."( Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
Azimioara, M; Cow, C; Cuc Ngo, C; Epple, R; Gerken, A; Huang, D; Iskandar, M; Karanewsky, DS; Nguyêñ-Trân, VT; Russo, R; Saez, E; Seidel, HM; Spalding, T; Tian, SS; Tuntland, T; Wang, X; Wityak, J; Xie, Y, 2010
)
0.36
" A second smaller exploratory study (n=37) in a similar population was conducted using a sequence of 5 and 10 mg dosing for the assessment of lipoprotein particle concentration."( Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Jones, NP; Olson, EJ; Pearce, GL; Sprecher, DL, 2012
)
0.38
" Exposure of HepG2 cells transiently transfected with a PPARδ expression plasmid and a PPAR-response element-driven luciferase reporter plasmid to PPARδ agonists GW501516, GW610742 and L-165041 resulted in clear dose-response curves."( Bioactivity screening and mass spectrometric confirmation for the detection of PPARδ agonists that increase type 1 muscle fibres.
Blokland, M; Bovee, TF; Essers, ML; Hamers, AR; Heskamp, HH; Kersten, S; Nielen, MW; van Ginkel, LA, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
PPARbeta/delta agonistA PPAR modulator which activates the peroxisome proliferator-activated receptor-beta/delta.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
1,3-thiazoles
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency12.83660.001310.157742.8575AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)IC50 (µMol)5.04870.00501.205110.0000AID1798911; AID348374; AID591222; AID665205
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)IC50 (µMol)0.80740.00100.85056.3100AID156625; AID1798911; AID299417; AID348375; AID459604; AID591220; AID665204
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)Ki0.01760.00000.51413.1623AID1451024; AID1673239; AID1701619; AID1870348; AID1918901
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)IC50 (µMol)2.10840.00050.82696.3100AID1798911; AID1798912; AID299418; AID348373; AID591221; AID665203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C9 Homo sapiens (human)EC50 (µMol)0.40000.00080.41702.3000AID1398472
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)2.50000.00021.397110.0000AID156452
Cytochrome P450 2C19Homo sapiens (human)EC50 (µMol)1.50000.00030.00600.0123AID1398473
Peroxisome proliferator-activated receptor deltaMus musculus (house mouse)EC50 (µMol)0.05940.02001.53507.2000AID1370285; AID156784; AID1878214; AID280994; AID469797
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)5.13490.00000.992210.0000AID1370284; AID1398473; AID156945; AID1798916; AID1798920; AID1878212; AID268885; AID270380; AID277150; AID288975; AID299623; AID308432; AID417012; AID551966; AID552196; AID597761; AID635239; AID663628
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)1.00000.00031.654210.0000AID157278
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)EC50 (µMol)0.34210.00020.84609.1000AID1168704; AID1201426; AID1323523; AID1370282; AID1398471; AID1467411; AID156617; AID1630665; AID1650500; AID1663958; AID1753551; AID1798916; AID1798920; AID1822056; AID1878213; AID1918910; AID268884; AID270378; AID277149; AID280960; AID288974; AID299420; AID299625; AID308146; AID308433; AID348376; AID417011; AID469785; AID469789; AID551019; AID551967; AID552401; AID591223; AID597762; AID635240; AID662545; AID663629; AID663659
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)2.72900.00061.607410.0000AID1370283; AID1398472; AID156147; AID1798916; AID1798920; AID1878211; AID268883; AID270379; AID277148; AID280956; AID288973; AID299621; AID308431; AID417010; AID551965; AID552193; AID597760; AID635238; AID663627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (149)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (58)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (284)

Assay IDTitleYearJournalArticle
AID299621Agonist activity at human PPARalpha by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID1701615Binding affinity to PPAR-alpha (unknown origin) assessed as ligand replacement at 30 uM by TR-FRET assay relative to control
AID268885Agonist activity at PPARgamma by transactivation assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.
AID268885Agonist activity at PPARgamma by transactivation assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
AID663659Binding affinity at human GST-tagged PPARdelta ligand binding domain after 1 hr by time-resolved FRET analysis2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID1650500Competitive binding affinity to GST-tagged human PPARdelta LBD incubated for 1 to 6 hrs by TR-FRET assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
AID417010Agonist activity at PPARalpha ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Selective, potent PPARgamma agonists with cyclopentenone core structure.
AID1467411Agonist activity at GAL4N fused human PPARdelta LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
AID375486Decrease in insulin level in obese rhesus monkey administered orally at 0.1 mg/kg for 4 weeks followed by rising to 0.3, 1.0, 3.0 mg/kg during sequential 4-week period2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
AID1878205Transactivation of Gal4-fused human PPARalpha expressed in CHO cells co expressing pG5-Luc reporter at 1 uM2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID552191Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay relative to WY-146432011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID280994Agonist activity at mouse PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID591224Partial agonist activity at human PPARdelta expressed in african green monkey CV1 cells transfected with Gal4 assessed as beta-galactosidase activity by transactivation assay relative to control2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
AID348373Displacement of radiolabeled ligand from human PPARalpha by competition-binding assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID299418Displacement of [3H]2-(4-(2-(3-(2,4-difluorophenyl)-1-heptylureido)ethyl)phenoxy)-2-methylbutanoic acid from human PPARalpha after 30 mins by SPA2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
AID1370368Reversal of thermal injury-induced muscle damage in C57BL/6 mouse assessed as reduction in Evans blue dye retention time at 10 mg/kg, po administered once daily via gavage treated for 10 days prior to thermal injury on day 4 and subsequent Evans blue dye 2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1451024Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARdelta LBD by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID288973Effect on PPARalpha transactivation activity in HEK293 cells2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
AID459604Antagonist activity at human PPARdelta ligand binding domain-mediated transcriptional activity in CV1 cells by Gal4 chimera reporter assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.
AID1665608AUC (0.5 to 6 hrs) in C57BL/6 mouse brain at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID469796Upregulation of PDK4 expression in C57BL/6 mouse at 10 mg/kg, po qd relative to control2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID1370367Modulatory activity at PPARdelta in human primary muscle cells assessed as effect on PDK4 gene expression at EC50 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1870347Binding affinity to PPARgamma (unknown origin) by TR-FRET based LanthaScreen competitive binding assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
AID375484Decrease in low density lipoprotein level in obese rhesus monkey administered orally at 0.1 mg/kg for 4 weeks followed by rising to 0.3, 1.0, 3.0 mg/kg during sequential 4-week period2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
AID469797Agonist activity at mouse PPARdelta by FRET assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID308146Agonist activity at human PPARdelta receptor expressed in HEK293 cells by GAL4 transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.
AID552196Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID281017Decrease in glucose level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID365546Agonist activity at PPARdelta expressed in human HepG2 cells at 2 nM assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID156617Maximum transcriptional activation of human PPAR delta receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID469793Cmax in C57BL/6 mouse at 10 mg/kg, po qd2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID280001Increase of plasma HDLc level in female human apoA1 transgenic mouse at 10 mg/kg2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID288975Effect on PPARgamma transactivation activity in HEK293 cells2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
AID552194Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay relative to rosiglitazone2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID1878213Transactivation of Gal4-fused human PPARdelta expressed in CHO cells co expressing pG5-Luc reporter2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID299420Agonist activity at human PPARdelta in HepG2 cells by GAL4-luciferase reporter gene assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
AID1201426Agonist activity at pSG5-Gal4-tagged human PPAR-beta/delta ligand binding domain expressed in COS1 cells assessed as receptor activation incubated for 19 hrs by pGL3-5XUAS-SV40 luciferase reporter gene assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618.
AID1878223Anti-obesity activity in d/db mouse assessed as HDL cholesterol level at 30 mg/kg, po for 8 days (Rvb = 103.5 +/- 3.2 %)2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID308432Agonist activity at human PPARgamma by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design of a partial PPARdelta agonist.
AID746615Agonist activity at PPARdelta (unknown origin) transfected in HEK293 cells at 100 nM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID348375Displacement of [3H]GW 2433 from human PPARdelta by competition-binding assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID552401Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID469795Upregulation of UCP3 expression in C57BL/6 mouse at 10 mg/kg, po qd relative to control2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID299421Selectivity for human PPARdelta over human PPARalpha2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
AID1663958Agonist activity at PPARdelta (unknown origin)2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.
AID551965Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1673248Induction of adipogenesis in human BMMSC cells assessed as increase in ACOX1 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID597762Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID469789Agonist activity at human PPARdelta ligand binding domain by FRET assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID1673225Induction of adipogenesis in human BMMSC cells assessed as increase in ACACB mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1878214Transactivation of Gal4-fused mouse PPARdelta expressed in CHO cells co expressing pG5-Luc reporter2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID1451001Agonist activity at PPARdelta in human bone marrow-derived mesenchymal stem cells assessed as induction of PDK4 mRNA levels at 10 uM after 2 days by qRT-PCR method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID469791AUC ((0 to 24 hrs)) in C57BL/6 mouse at 10 mg/kg, po qd2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID348376Agonist activity at human PPARdelta by Gal4 chimera cell-based reporter assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID551020Selectivity ratio of EC50 for human PPARalpha DNA binding domain to EC50 for PPARdelta DNA binding domain2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.
AID308435Agonist activity at human PPARgamma by transactivation assay relative to rosiglitazone2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design of a partial PPARdelta agonist.
AID1753550Agonist activity at human Gal4 fused PPARalpha LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
AID417011Agonist activity at PPARdelta ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Selective, potent PPARgamma agonists with cyclopentenone core structure.
AID299417Displacement of [3H]2-(4-(3-(4-acetyl-3-hydroxy-2 propyl-phenoxy)propoxy)phenoxy)acetic acid from human PPARdelta after 30 mins by SPA2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
AID375485Decrease in triglyceride level in obese rhesus monkey administered orally at 0.1 mg/kg for 4 weeks followed by rising to 0.3, 1.0, 3.0 mg/kg during sequential 4-week period2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
AID299624Agonist activity at human PPARgamma by transactivation assay relative to rosiglitazone2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID551877Agonist activity at human PPARdelta in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 10 uM by luciferase reporter gene assay relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
AID591221Displacement of [3H]GW 2433 from human PPARalpha by scintillation proximity assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
AID662545Transactivation of human PPARdelta expressed in african green monkey CV1 cells by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1370410Tumorigenic activity in rat assessed as proliferation index in non-glandular stomach at 30 mg/kg administered for 14 days measured on post last dose by Ki-67 staining based histopathological analysis (Rvb = 35.7 to 49.2 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID348508Agonist activity at human PPARdelta ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 0.2 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID1370412Tumorigenic activity in rat assessed as proliferation index in non-glandular stomach at 300 mg/kg administered for 6 days and subsequent treatment at 200 mg/kg for 3 days measured on post last dose by Ki-67 staining based histopathological analysis (Rvb =2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID308434Agonist activity at human PPARalpha by transactivation assay relative to NNC61-46552007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design of a partial PPARdelta agonist.
AID1370420AUC (0 to last) in rat at 30 mg/kg2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID663627Transactivation activity at human PPARalpha expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID1543215Agonist activity at human PPARgamma expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to rosiglitazone
AID1370415Tumorigenic activity in rat assessed as effect on cell proliferation in non-glandular stomach at 100 mg/kg administered for 14 days measured on post last dose by Ki-67 staining based histopathological analysis relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID597765Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.03 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID1543216Agonist activity at human PPARbeta/delta expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to GW501516
AID348506Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 10 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID281029Effect on increase in fatty acid oxidation in rat L6 cells relative to basal2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID281009Decrease in triglycerides level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID597763Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.1 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID156147Maximum transcriptional activation of human PPAR alpha receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID288974Effect on PPARdelta transactivation activity in HEK293 cells2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
AID1467412Agonist activity at GAL4N fused human PPARdelta LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay relative to GW5015162017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
AID469785Agonist activity at human PPARdelta ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID459605Antagonist activity at human PPARdelta ligand binding domain-mediated transcriptional activity in CV1 cells by Gal4 chimera reporter assay relative to control2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.
AID1878225Anti-diabetic activity in d/db mouse assessed as glucose level at 30 mg/kg, po for 8 days (Rvb = 737 +/- 52 mg/dL)2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID277149Agonist potency at PPARdelta in CV1 cells by cell based transient transfection assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1870348Binding affinity to PPARdelta (unknown origin) by TR-FRET based LanthaScreen competitive binding assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
AID551703Agonist activity at human PPARgamma in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 0.2 uM by luciferase reporter gene assay relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
AID1753552Agonist activity at human Gal4 fused PPARgamma LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
AID552193Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID1673228Induction of adipogenesis in human BMMSC cells assessed as increase in HMGCR mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1370284Transactivation of GAL4-fused human PPARgamma LBD expressed in African green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID375487Increase in high density lipoprotein level in obese rhesus monkey administered orally at 0.1 mg/kg for 4 weeks followed by rising to 0.3, 1.0, 3.0 mg/kg during sequential 4-week period2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
AID1878212Transactivation of Gal4-fused human PPARgamma expressed in CHO cells co expressing pG5-Luc reporter2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID268883Agonist activity at PPARalpha by transactivation assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.
AID268883Agonist activity at PPARalpha by transactivation assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
AID156452Activity against murine PPAR alpha receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID156945Maximum transcriptional activation of human PPAR gamma receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID1665619AUC (0.5 to 6 hrs) in C57BL/6 mouse serum at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID551702Agonist activity at human PPARalpha in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 10 uM by luciferase reporter gene assay relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
AID226985Selectivity for human PPAR delta over for PPAR alpha receptor was measured2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID1451030Transactivation of human GST-tagged PPARalpha LBD assessed as fluorescein-C33 coactivator recruitment by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID280960Activity at human placenta PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID279999Reduction of plasma triglyceride level in male human apoA1 transgenic mouse at 10 mg/kg2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID348507Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 0.2 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID1370357Thermodynamic solubility of the compound2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1451020Transrepression of human GST-tagged PPARdelta LBD assessed as induction of corepressor SMRT-ID2 peptide recruitment at 1 uM by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID591222Displacement of [3H]GW 2433 from human PPARgamma by scintillation proximity assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
AID1673221Induction of adipogenesis in human BMMSC cells assessed as increase in ANGPTL4 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID551967Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.
AID281001Increase in HDL level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID156784Activity against murine PPAR delta receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID280963Effect on fatty acid oxidation in rat L6 cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID299625Agonist activity at human PPARdelta by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID270379Activity at PPARalpha by luciferase reporter gene transactivation assay in COS7 cells2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID1701619Binding affinity to PPAR-delta (unknown origin) by TR-FRET assay
AID1370282Transactivation of GAL4-fused human PPARdelta LBD expressed in African green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID665204Agonist activity at PPARdelta2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Activity landscape modeling of PPAR ligands with dual-activity difference maps.
AID1878224Anti-obesity activity in d/db mouse assessed as TG level at 30 mg/kg, po for 8 days (Rvb = 162.8 +/- 21.4 mg/dL)2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID1370422AUC (0 to last) in rat at 300 mg/kg measured on day 82018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1753551Agonist activity at human Gal4 fused PPARdelta LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
AID157278Activity against murine PPAR gamma receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID280000Increase of plasma HDLc level in male human apoA1 transgenic mouse at 10 mg/kg2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID551966Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.
AID281013Decrease in total ketone bodies level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID308433Agonist activity at human PPARdelta by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design of a partial PPARdelta agonist.
AID308431Agonist activity at human PPARalpha by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design of a partial PPARdelta agonist.
AID597760Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID1370414Tumorigenic activity in rat assessed as effect on cell proliferation in non-glandular stomach at 30 mg/kg administered for 14 days measured on post last dose by Ki-67 staining based histopathological analysis relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID280961Activity at human placenta PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay relative to carbacyclin2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID277150Agonist potency at PPARgamma in CV1 cells by cell based transient transfection assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID281025Decrease in HbA1c level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID746616Agonist activity at PPARalpha (unknown origin) transfected in HEK293 cells at 100 nM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID308145Agonist activity at human PPARalpha receptor expressed in HEK293 cells upto 10 uM by GAL4 transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.
AID226986Selectivity for human PPAR delta over PPAR gamma receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID1370411Tumorigenic activity in rat assessed as proliferation index in non-glandular stomach at 100 mg/kg administered for 14 days measured on post last dose by Ki-67 staining based histopathological analysis (Rvb = 35.7 to 49.2 No_unit)2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1370416Tumorigenic activity in rat assessed as effect on cell proliferation in non-glandular stomach at 300 mg/kg administered for 6 days and subsequent treatment at 200 mg/kg for 3 days measured on post last dose by Ki-67 staining based histopathological analys2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1630665Agonist activity at N-terminal Gal4 fused human PPARdelta LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
AID1398472Transactivation of human PPARalpha expressed in monkey CV-1 cells coexpressing TK-PPRE-Luc after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
AID1870346Binding affinity to PPARalpha (unknown origin) by TR-FRET based LanthaScreen competitive binding assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
AID665205Agonist activity at PPARgamma2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Activity landscape modeling of PPAR ligands with dual-activity difference maps.
AID469792Half life in C57BL/6 mouse at 10 mg/kg, po qd2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID308150Agonist activity at human PPARgamma receptor expressed in HEK293 cells upto 10 uM by GAL4 transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.
AID551019Agonist activity at Gal4-fused human PPARdelta DNA binding domain expressed in HEK293 cells by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.
AID552400Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity at 10 uM after 20 to 22 hrs by luciferase based transactivation assay relative to control2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID277152Agonist potency at PPARdelta in CV1 cells relative to GW-5015162007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1673239Binding affinity to PPARdelta (unknown origin) by TR-FRET assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID490433Induction of [14C]-oleic acid oxidation in human differentiated skeletal muscle cells assessed as accumulation of oxidized [14C]-oleic acid after 4 hrs by by liquid scintillation counting2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516.
AID280993Effect on glucose oxidation in rat L6 cells2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID1878211Transactivation of Gal4-fused human PPARalpha expressed in CHO cells co expressing pG5-Luc reporter2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID662550Binding affinity to GST-tagged human PPARgamma by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID280981Clearance in Sprague-Dawley rat at 1.09 mg/kg, iv2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID280958Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID746614Agonist activity at PPARgamma (unknown origin) transfected in HEK293 cells at 100 nM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1370283Transactivation of GAL4-fused human PPARalpha LBD expressed in African green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID277148Agonist potency at PPARalpha in CV1 cells by cell based transient transfection assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1878210Transactivation of Gal4-fused mouse PPARdelta expressed in CHO cells co expressing pG5-Luc reporter at 1 uM2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID270380Activity at PPARgamma by luciferase reporter gene transactivation assay in COS7 cells2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID280957Activity at human liver PPAR alpha expressed in HEK293 cells by GAL4 transactivation assay relative to NNC61-46552007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID1370418Toxicity in rat assessed as reduction in body weight at 300 mg/kg administered for 6 days2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID280976Oral bioavailability in Sprague-Dawley rat at 2.13 mg/kg2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID1370366Modulatory activity at PPARdelta in human primary muscle cells assessed as effect on ANGPTL4 gene expression at EC50 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID268884Agonist activity at PPARdelta by transactivation assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.
AID268884Agonist activity at PPARdelta by transactivation assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
AID490435Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells co-transfected with Gal4 at 10 uM by luciferase reporter gene assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516.
AID1665630Brain to serum concentration ratio, Kp of the compound in C57BL/6 mouse at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID299623Agonist activity at human PPARgamma by transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID156625Binding affinity for human PPAR delta receptor2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
AID1878207Transactivation of Gal4-fused human PPARgamma expressed in CHO cells co expressing pG5-Luc reporter at 1 uM2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID277151Agonist potency at PPARalpha expressed in CV1 cells relative to GW-5907352007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID469788Agonist activity at human PPARdelta ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to GW-5015162010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID552197Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay relative to GW-5015162011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID1370365Modulatory activity at PPARdelta in human primary muscle cells assessed as effect on CPT1A gene expression at EC50 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID417012Agonist activity at PPARgamma ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Selective, potent PPARgamma agonists with cyclopentenone core structure.
AID665203Agonist activity at PPARalpha2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Activity landscape modeling of PPAR ligands with dual-activity difference maps.
AID635239Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
AID1370285Transactivation of mouse PPARdelta by cell-based luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID1673226Induction of adipogenesis in human BMMSC cells assessed as increase in HMGCS2 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1398473Transactivation of human PPARgamma expressed in monkey CV-1 cells coexpressing TK-PPRE-Luc after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
AID299419Displacement of [3H]5-(4-(3-(5-methyl-2-phenyloxazol-4-yl)propanoyl)benzyl)thiazolidine-2,4-dione from human PPARgamma after 2 hrs by SPA2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
AID1451000Agonist activity at PPARdelta in human bone marrow-derived mesenchymal stem cells assessed as induction of ANGPTL4 mRNA levels at 10 uM after 2 days by qRT-PCR method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1878209Transactivation of Gal4-fused human PPARdelta expressed in CHO cells co expressing pG5-Luc reporter at 1 uM2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
AID1370421AUC (0 to last) in rat at 100 mg/kg2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID635240Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
AID280970Plasma Cmax in Sprague-Dawley rat at 2.13 mg/kg, po2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID663631Selectivity ratio of EC50 for human PPARgamma to EC50 for human PPARdelta2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID662549Binding affinity to GST-tagged human PPARalpha by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID270383Activity at PPARgamma by luciferase reporter gene transactivation assay in COS7 cells relative to rosiglitazone at 1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID280959Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay relative to rosiglitazone2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1398471Transactivation of human PPARdelta expressed in monkey CV-1 cells coexpressing TK-PPRE-Luc after 24 hrs by luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
AID308796Increase in serum HDL level in hApoA1 mouse model at 10 mg/kg, po2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Indanylacetic acids as PPAR-delta activator insulin sensitizers.
AID270382Activity at PPARalpha by luciferase reporter gene transactivation assay in COS7 cells relative to WY-14643 at 10 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID635193Induction of [14C]oleic acid oxidation in a human myotubes after 4 days by beta liquid scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
AID299622Agonist activity at human PPARalpha by transactivation assay relative to NNC 61-46552007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID635238Agonist activity at human PPARalpha ligand binding domain expressed in COS-1 cells co-transfected with Gal4 after 24 hrs by luciferase reporter gene assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
AID469798Agonist activity at mouse PPARdelta by FRET assay relative to GW-5015162010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID1543217Agonist activity at human RXRalpha expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to 9-cis-retinoic acid
AID280997Decrease in total cholesterol level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID1370419Toxicity in rat assessed as effect on food intake at 300 mg/kg administered for 6 days2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.
AID270381Activity at PPARbeta/delta by luciferase reporter gene transactivation assay in COS7 cells relative to MWI66 at 1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID551021Selectivity ratio of EC50 for human PPARgamma DNA binding domain to EC50 for PPARdelta DNA binding domain2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.
AID1168704Agonist activity at human PPARbeta expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1543214Agonist activity at human PPARalpha expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to WY-14643
AID469790Agonist activity at human PPARdelta ligand binding domain by FRET assay relative to GW-5015162010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
AID270378Activity at PPARbeta/delta by luciferase reporter gene transactivation assay in COS7 cells2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Studies towards the conception of new selective PPARbeta/delta ligands.
AID281021Decrease in insulin level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks by ELISA relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID1701616Binding affinity to PPAR-gamma (unknown origin) assessed as ligand replacement at 30 uM by TR-FRET assay relative to control
AID1918910Partial agonist activity at PPARdelta (unknown origin) assessed as increase in fluorescein labeled PRIP/RAP250 coactivator peptide requirement by Lanthascreen TR-FRET assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus,
AID597764Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.01 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID280986Volume of distribution in Sprague-Dawley rat at 1.09 mg/kg, iv2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID348374Displacement of radiolabeled ligand from human PPARgamma by competition-binding assay2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID1918901Binding affinity to PPARdelta (unknown origin) assessed as inhibition constant by Cheng-Prusoff equation analysis2022Journal of natural products, 12-23, Volume: 85, Issue:12
Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus,
AID591220Displacement of [3H]GW 2433 from human PPARdelta by scintillation proximity assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
AID281005Decrease in LDL level in human ApoB100/CETP transgenic mouse at 6 mg/kg, po after 6 weeks relative to control2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID280992Half life in Sprague-Dawley rat at 2.13 mg/kg, po2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID277153Agonist potency at PPARgamma in CV1 cells relative to rosiglitazone2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID591223Partial agonist activity at human PPARdelta expressed in african green monkey CV1 cells transfected with Gal4 assessed as beta-galactosidase activity by transactivation assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
AID308797Decrease in serum triglyceride level in hApoA1 mouse model at 10 mg/kg, po2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Indanylacetic acids as PPAR-delta activator insulin sensitizers.
AID299626Agonist activity at human PPARdelta by transactivation assay relative to carbacyclin2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
AID597761Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID663629Transactivation activity at human PPARdelta expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID280956Activity at human liver PPAR alpha expressed in HEK293 cells by PPAR-GAL4 transactivation assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID663628Transactivation activity at human PPARgamma expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID348377Agonist activity at human PPARdelta by Gal4 chimera cell-based reporter assay relative to GW-5015162008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID1701613Displacement of [125I]I-AB-MECA from recombinant human A3AR expressed in CHO cell membranes measured after 60 mins by gamma counter analysis
AID1323523Agonist activity at GAL4-tagged human PPARdelta ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic activity.
AID1822056Agonist activity at PPARdelta (unknown origin)
AID277183Selectivity for PPARalpha over PPARdelta2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID663630Selectivity ratio of EC50 for human PPARalpha to EC50 for human PPARdelta2012European journal of medicinal chemistry, Jul, Volume: 53Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1798916Cell-Based Transcription Assay from Article 10.1021/jm058056x: \\Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.\\2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1798920Cell-Based Transcription Assay from Article 10.1021/jm070511x: \\Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.\\2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
AID1798911Radioligand Binding Assay (IC50) and Cell-Based Transcription Assay (EC50) from Article 10.1016/j.bmcl.2008.08.011: \\Discovery of a novel class of PPARdelta partial agonists.\\2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID1798912Radioligand Binding Assay from Article 10.1016/j.bmcl.2008.08.011: \\Discovery of a novel class of PPARdelta partial agonists.\\2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Discovery of a novel class of PPARdelta partial agonists.
AID1346790Human Peroxisome proliferator-activated receptor-beta/delta (1C. Peroxisome proliferator-activated receptors)2001Proceedings of the National Academy of Sciences of the United States of America, Apr-24, Volume: 98, Issue:9
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (283)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's93 (32.86)29.6817
2010's155 (54.77)24.3611
2020's35 (12.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.74%)5.53%
Reviews18 (6.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other264 (91.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]